NQTrp

NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide (41GCWMLY46 within the N-terminus of γD-crystallin) as well as full-length γD-crystallin[1].

Product Specifications

CAS Number

[185351-19-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Tau Protein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/nqtrp.html

Purity

98.37

Solubility

DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(O)[C@H](CC1=CNC2=CC=CC=C12)NC(C3=O)=CC(C4=C3C=CC=C4)=O

Molecular Formula

C21H16N2O4

Molecular Weight

360.36

Precautions

H302, H315, H319, H335

References & Citations

[1]Malak Abu-Hussien, et al. An amyloidogenic hexapeptide from the cataract-associated γD-crystallin is a model for the full-length protein and is inhibited by naphthoquinone-tryptophan hybrids. Int J Biol Macromol. 2020 Aug 15;157:424-433.